Alpha Tau Medical Statistics
Total Valuation
DRTS has a market cap or net worth of $1.39 billion. The enterprise value is $1.30 billion.
| Market Cap | 1.39B |
| Enterprise Value | 1.30B |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRTS has 92.33 million shares outstanding. The number of shares has increased by 20.98% in one year.
| Current Share Class | 92.33M |
| Shares Outstanding | 92.33M |
| Shares Change (YoY) | +20.98% |
| Shares Change (QoQ) | +1.39% |
| Owned by Insiders (%) | 14.91% |
| Owned by Institutions (%) | 8.95% |
| Float | 64.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 415.91 |
| PB Ratio | 31.50 |
| P/TBV Ratio | 31.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.09, with a Debt / Equity ratio of 0.34.
| Current Ratio | 11.09 |
| Quick Ratio | 10.45 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -140.08 |
Financial Efficiency
Return on equity (ROE) is -141.68% and return on invested capital (ROIC) is -39.61%.
| Return on Equity (ROE) | -141.68% |
| Return on Assets (ROA) | -25.71% |
| Return on Invested Capital (ROIC) | -39.61% |
| Return on Capital Employed (ROCE) | -40.47% |
| Weighted Average Cost of Capital (WACC) | 10.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$765,074 |
| Employee Count | 121 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DRTS has paid $175,000 in taxes.
| Income Tax | 175,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +325.78% in the last 52 weeks. The beta is 1.18, so DRTS's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +325.78% |
| 50-Day Moving Average | 13.30 |
| 200-Day Moving Average | 8.78 |
| Relative Strength Index (RSI) | 62.60 |
| Average Volume (20 Days) | 666,189 |
Short Selling Information
The latest short interest is 3.06 million, so 3.31% of the outstanding shares have been sold short.
| Short Interest | 3.06M |
| Short Previous Month | 3.21M |
| Short % of Shares Out | 3.31% |
| Short % of Float | 4.77% |
| Short Ratio (days to cover) | 5.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.43M |
| Pretax Income | -92.40M |
| Net Income | -92.57M |
| EBITDA | -48.76M |
| EBIT | -50.43M |
| Earnings Per Share (EPS) | -$1.05 |
Balance Sheet
The company has $100.64 million in cash and $15.15 million in debt, with a net cash position of $85.49 million or $0.93 per share.
| Cash & Cash Equivalents | 100.64M |
| Total Debt | 15.15M |
| Net Cash | 85.49M |
| Net Cash Per Share | $0.93 |
| Equity (Book Value) | 44.06M |
| Book Value Per Share | 0.48 |
| Working Capital | 97.20M |
Cash Flow
In the last 12 months, operating cash flow was -$12.81 million and capital expenditures -$3.30 million, giving a free cash flow of -$16.11 million.
| Operating Cash Flow | -12.81M |
| Capital Expenditures | -3.30M |
| Depreciation & Amortization | 1.67M |
| Net Borrowing | n/a |
| Free Cash Flow | -16.11M |
| FCF Per Share | -$0.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.98% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.67% |
| FCF Yield | -1.16% |
Analyst Forecast
The average price target for DRTS is $14.40, which is -4.19% lower than the current price. The consensus rating is "Buy".
| Price Target | $14.40 |
| Price Target Difference | -4.19% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |